BRPI0412707A - partìculas contendo um agente ativo na forma de um coprecipitado - Google Patents

partìculas contendo um agente ativo na forma de um coprecipitado

Info

Publication number
BRPI0412707A
BRPI0412707A BRPI0412707-2A BRPI0412707A BRPI0412707A BR PI0412707 A BRPI0412707 A BR PI0412707A BR PI0412707 A BRPI0412707 A BR PI0412707A BR PI0412707 A BRPI0412707 A BR PI0412707A
Authority
BR
Brazil
Prior art keywords
active agent
coprecipitate
particles containing
particles
precipitate
Prior art date
Application number
BRPI0412707-2A
Other languages
English (en)
Inventor
Gerard Cousin
Gaul Lamoureux
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Publication of BRPI0412707A publication Critical patent/BRPI0412707A/pt
Publication of BRPI0412707B1 publication Critical patent/BRPI0412707B1/pt
Publication of BRPI0412707B8 publication Critical patent/BRPI0412707B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PARTìCULAS CONTENDO UM AGENTE ATIVO NA FORMA DE UM CO-PRECIPITADO". A invenção refere-se a partículas contendo um agente ativo na forma de um co-precipitado, a um método de produção das referidas partículas e a formas farmacêuticas contendo as referidas partículas.
BRPI0412707A 2003-07-17 2004-07-16 processo para preparo de partículas contendo itraconazol na forma de um co-precipitado e partículas BRPI0412707B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0308720A FR2857591B1 (fr) 2003-07-17 2003-07-17 Particules comprenant un principe actif sous forme de co-precipite
PCT/FR2004/001878 WO2005009411A2 (fr) 2003-07-17 2004-07-16 Particules comprenant un principe actif sous forme de co-precipite

Publications (3)

Publication Number Publication Date
BRPI0412707A true BRPI0412707A (pt) 2006-09-26
BRPI0412707B1 BRPI0412707B1 (pt) 2018-11-27
BRPI0412707B8 BRPI0412707B8 (pt) 2021-05-25

Family

ID=33548203

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412707A BRPI0412707B8 (pt) 2003-07-17 2004-07-16 processo para preparo de partículas contendo itraconazol na forma de um co-precipitado e partículas

Country Status (10)

Country Link
US (2) US20060222715A1 (pt)
EP (1) EP1651188B1 (pt)
JP (1) JP4754485B2 (pt)
CN (1) CN1822818B (pt)
BR (1) BRPI0412707B8 (pt)
CA (1) CA2532626C (pt)
ES (1) ES2544626T3 (pt)
FR (1) FR2857591B1 (pt)
MX (1) MXPA06000614A (pt)
WO (1) WO2005009411A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124895D1 (de) * 2001-07-26 2007-01-11 Ethypharm Sa Umgehüllte Allylamine oder Benzylamine enthaltende Granulate, Verfahren zur Herstellung und in der Mundhöhle dispergierbare Tabletten enthaltend die umgehüllten Granulate
CN103717289A (zh) 2011-04-11 2014-04-09 Ada-Es股份有限公司 用于气体组分捕集的流化床方法和系统
US9278314B2 (en) 2012-04-11 2016-03-08 ADA-ES, Inc. Method and system to reclaim functional sites on a sorbent contaminated by heat stable salts
CA3057701C (en) * 2017-04-13 2022-07-05 The Procter & Gamble Company Product composition comprising a discrete particle and an aqueous base composition
EP4452232A1 (en) * 2021-12-22 2024-10-30 Palau Pharma, S.L.U. Multiparticulate albaconazole composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
JPS62221626A (ja) * 1986-03-20 1987-09-29 Tokyo Tanabe Co Ltd １，４−ジヒドロピリジン化合物の製剤用組成物
JP3492688B2 (ja) * 1992-10-09 2004-02-03 鐘淵化学工業株式会社 微細な造粒体の製造方法
JP3640980B2 (ja) * 1993-04-09 2005-04-20 株式会社林原生物化学研究所 ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法
DK0904060T3 (da) * 1996-05-20 2004-04-13 Janssen Pharmaceutica Nv Antifungale præparater med forbedret biotilgængelighed
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
UY26615A1 (es) * 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation

Also Published As

Publication number Publication date
EP1651188A2 (fr) 2006-05-03
BRPI0412707B1 (pt) 2018-11-27
WO2005009411A2 (fr) 2005-02-03
MXPA06000614A (es) 2006-04-11
CN1822818A (zh) 2006-08-23
US20060222715A1 (en) 2006-10-05
US20100266702A1 (en) 2010-10-21
JP2007528865A (ja) 2007-10-18
CA2532626A1 (fr) 2005-02-03
BRPI0412707B8 (pt) 2021-05-25
CA2532626C (fr) 2013-03-26
WO2005009411B1 (fr) 2005-05-26
WO2005009411A3 (fr) 2005-03-24
ES2544626T3 (es) 2015-09-02
EP1651188B1 (fr) 2015-05-06
JP4754485B2 (ja) 2011-08-24
CN1822818B (zh) 2012-07-25
FR2857591B1 (fr) 2007-11-02
FR2857591A1 (fr) 2005-01-21

Similar Documents

Publication Publication Date Title
BRPI0409623A (pt) produto farmacêutico, método de preparação do mesmo e uso de substáncias na preparação do referido produto farmacêutico
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
WO2003054130A3 (de) Polymere duftkapseln und ihre herstellung
FR2842201B1 (fr) Nouvel oligosaccharide, compositions cosmetiques et/ou dermatologiques en contenant et ses applications
PL378168A1 (pl) Dihydropterydynony, sposoby ich wytwarzania i ich zastosowanie w postaci leków
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
IL226313A0 (en) A method for producing gamma-carboxylated human prothrombin, isolated prothrombin produced by such a method, a pharmaceutical preparation including it and its use as drugs and for the production of drugs for the treatment of blood coagulation
CY1110061T1 (el) Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης
IL173204A0 (en) Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
ATE367152T1 (de) Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
ATE350461T1 (de) Riechstoffzusammensetzung
PL371784A1 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
ATE432710T1 (de) Pharmazeutische zusammensetzungen, die diaminooxidase enthalten
ATE487741T1 (de) Mischungen aus von heparin abgeleiteten oligosacchariden, herstellung davon und pharmazeutische zusammensetzungen, die die mischungen enthalten
BR0210632A (pt) Tratamento de doença parasìtica
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
BRPI0412707B8 (pt) processo para preparo de partículas contendo itraconazol na forma de um co-precipitado e partículas
BRPI0611526A2 (pt) composição tópica contendo gelatina
PL1713438T3 (pl) Mydło lecznicze
AU2003294952A8 (en) 3,3-dimethyl-8-oxoisoquinolines for medical purposes, methods for the production thereof, medicaments containing said compounds and the use of the same

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2731 DE 09-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.